Brain-Computer Interface Company Synchron Secures $200 Million
Synchron, a New York-based company specializing in non-surgical brain-computer interface (BCI) technology, announced it has raised $200 million in a Series D funding round.
Purpose of the Funding
The new capital will speed up commercialization of Synchron’s first-generation Stentrode BCI platform and support the development of a cutting-edge next-generation interface.
Funding Details
- Total funding for Synchron has now reached $345 million.
- Double Point Ventures led the Series D round.
- Existing investors include ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS.
- New investors comprise the Australian National Reconstruction Fund (NRF), T.Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
The Stentrode BCI Platform
Synchron’s Stentrode is the first endovascular brain-computer interface designed to convert brain signals into digital commands without the need for open-brain surgery.
Placed via a non-surgical catheter procedure, the Stentrode interfaces with the motor cortex through blood vessels, recording and wirelessly transmitting neural signals to enable hands-free digital device control.
Significance
This innovative approach allows users to control technology without invasive brain surgery, representing a major advance in BCI technology.
Author's summary: Synchron’s $200 million funding boost aims to accelerate market launch of its groundbreaking Stentrode brain-computer interface, shifting BCI toward less invasive, wireless control.